Kandi Technologies Reports First Quarter 2024 Financial Results
Solid Start to the Year with Net Income of $0.8 million, up 27.6% YoY Significant Return of Capital to Shareholders […]
ChampionX Declares Quarterly Dividend
THE WOODLANDS, Texas, May 16, 2024 (GLOBE NEWSWIRE) — ChampionX Corporation (Nasdaq: CHX) announced today its Board of Directors has […]
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic […]
OpGen Announced 1-for-10 Reverse Stock Split
ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the […]
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk […]
First Wave BioPharma Changes Name to Entero Therapeutics
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac […]
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
ALACHUA, Fla. and TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing […]
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing […]
Liquidity Services Announces Participation in Upcoming Investor Conferences
BETHESDA, Md., May 16, 2024 (GLOBE NEWSWIRE) — Liquidity Services (NASDAQ:LQDT), a leading global commerce company powering the circular economy, […]
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), […]
